ADME/PK profiling capabilities
Syngene, with its comprehensive suite of DMPK profiling assays, can help you achieve a high rate of success with your clinical candidates across drug modalities.
Choosing the ‘right’ CRO-CDMO in Biopharma – What has changed
Learn the new criteria that have emerged as more important for selecting an outsourcing partner consequent to disruptions caused by the COVID-19 pandemic.
How Syngene is implementing Green Chemistry in pharmaceutical development – Design to Delivery
Learn how Syngene is helping pharma companies minimize environmental impact using its Green Chemistry approach to drug development.
How Syngene synthesized a complex cyclic peptide for use in novel drug therapies
Learn how Syngene’s novel approach helped synthesize a complex 11-mer cyclic peptide for use in drug therapies.
How Syngene delivered pre-IND to IND Safety studies for a leading biotech company in just three months
Learn how Syngene partnered with a biotech company to deliver pre-IND to IND Safety studies in just three months for a treatment therapy for gut-brain diseases.
Targeted Protein Modulators – Cellular to ADME to PK/PD models and correlations
Presenting the cellular translation to degradation and functional response across different assay platforms using a PROTAC tool SynTAC-ERD, an Estrogen Receptor (ER) degrader.
Five questions that determine the success of your PROTAC programs
Challenges in developing PROTACs and critical questions that need to be addressed to move PROTAC molecules from Target to IND successfully.
Transforming Supply Chain risks into a competitive advantage in the CRO-CDMO space-The Syngene story
Learn how Syngene built a biopharma supply chain that is fast, resilient, and future-proof and, in the process, turned supply chain risks into a competitive advantage.
Solving problems with science: Gene to GMP-grade clinical supply in nine months
How Syngene’s proprietary data platform is safely and efficiently reducing the time taken to produce mAbs from gene to GMP-grade clinical supply by several months.
How Syngene’s safety tox package helped Cytopeutics to advance its cell therapy drug to the Clinic
Learn how Cytopeutics partnered with Syngene to conduct safety and tumorigenicity studies for its hMSC product in appropriate animal models as per regulatory guidelines.